← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 10.5% to $5.94B, while Net income increased 24.2% to $566.2M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $5.94BOK
- Profitability — Net income $566.2MOK
- Cash generation — Free cash flow N/ANote
- Accounting — Distress score not computed · no manipulation flag · earnings quality not computedNote
- Insiders — 0 buys; 5 sells in 365 daysNote
- Capital — dividends paid were $71.1M; share repurchases were $158.0MNote
Business
Encompass Health Corp: Reimbursement Risks Reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our inability to obtain and retain favorable arrangements with third-party payors, could decrease our revenues and adversely affect other operating results.
Where the revenue comes from
Fiscal 2025, as Encompass Health Corp reports it. History and quarterly detail are in the app.
- Inpatient$5.8B
- Other$178.9M
Leadership changes
From Encompass Health Corp's own filings, the day they're filed.
- Patricia Maryland · directors · departureeff. 2025-09-17
- Cain A. Hayes · director · appointment
- Edward M. Christie III · director · appointment
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-01
- 8-K · Company announcement2026-05-15
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Encompass Health Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.